Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 3942

1.

Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.

Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, Rylander E, Dillner J.

J Natl Cancer Inst. 2009 Jan 21;101(2):88-99. doi: 10.1093/jnci/djn444. Epub 2009 Jan 13.

PMID:
19141778
2.

Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial.

Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, Dalla Palma P, Del Mistro A, Folicaldi S, Gillio-Tos A, Nardo G, Naldoni C, Schincaglia P, Zorzi M, Confortini M, Cuzick J; New Technologies for Cervical Cancer Working Group..

J Natl Cancer Inst. 2006 Jun 7;98(11):765-74.

PMID:
16757701
3.

Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.

Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A.

J Natl Cancer Inst. 2009 Dec 2;101(23):1612-23. doi: 10.1093/jnci/djp367. Epub 2009 Nov 9.

PMID:
19903804
4.

Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia.

Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J.

J Natl Cancer Inst. 2004 Feb 18;96(4):280-93.

PMID:
14970277
5.

Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.

Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM.

Lancet Oncol. 2011 Sep;12(9):880-90. doi: 10.1016/S1470-2045(11)70188-7. Epub 2011 Aug 22.

PMID:
21865084
6.

Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.

Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman M.

J Natl Cancer Inst. 2003 Jan 1;95(1):46-52.

PMID:
12509400
7.

Human papillomavirus (HPV) testing in the management of women with abnormal Pap smears. Experience of a colposcopy referral clinic.

Ciotti M, Sesti F, Paba P, Benedetto A, Patrizi L, Criscuolo A, Piccione E, Branca M, Syrjänen K, Favalli C.

Eur J Gynaecol Oncol. 2004;25(5):577-84.

PMID:
15493169
8.

Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS).

Kulasingam SL, Kim JJ, Lawrence WF, Mandelblatt JS, Myers ER, Schiffman M, Solomon D, Goldie SJ; ALTS Group..

J Natl Cancer Inst. 2006 Jan 18;98(2):92-100.

PMID:
16418511
9.

Human papillomavirus and Papanicolaou tests to screen for cervical cancer.

Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Johansson B, Forslund O, Hansson BG, Rylander E, Dillner J.

N Engl J Med. 2007 Oct 18;357(16):1589-97. Erratum in: N Engl J Med. 2008 Oct 9;359(15):1637. Johansson, Bo [added].

10.

HPV testing in primary screening of older women.

Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I, Lorincz A, Chan WK, Krausz T, Soutter P.

Br J Cancer. 1999 Oct;81(3):554-8.

11.

[Combining high-risk human papillomavirus DNA test and cytological test to detect early cervical dysplasia].

Qian DY, Cen JM, Wang D, Zeng RH, Lin AH, Shu YH, Hong DH, Huang ZH.

Zhonghua Fu Chan Ke Za Zhi. 2006 Jan;41(1):34-7. Chinese.

PMID:
16635326
12.

Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.

Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlée F, Franco EL; Canadian Cervical Cancer Screening Trial Study Group..

N Engl J Med. 2007 Oct 18;357(16):1579-88.

13.

Value of high-risk HPV-DNA testing in the triage of ASCUS.

Silverloo I, Andrae B, Wilander E.

Acta Obstet Gynecol Scand. 2009;88(9):1006-10. doi: 10.1080/00016340903160952.

PMID:
19690991
14.

Screening for cervical cancer: new alternatives and research.

Lörincz AT.

Salud Publica Mex. 2003;45 Suppl 3:S376-87. Review.

PMID:
14746031
15.

Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation.

Verguts J, Bronselaer B, Donders G, Arbyn M, Van Eldere J, Drijkoningen M, Poppe W.

BJOG. 2006 Nov;113(11):1303-7. Epub 2006 Sep 15.

16.

Triage of women with ASCUS and LSIL on Pap smear reports: management by repeat Pap smear, HPV DNA testing, or colposcopy?

Ferris DG, Wright TC Jr, Litaker MS, Richart RM, Lorincz AT, Sun XW, Borgatta L, Buck H, Kramer L, Rubin R.

J Fam Pract. 1998 Feb;46(2):125-34.

PMID:
9487318
17.

High-risk HPV DNA detection by Hybrid Capture II. An adjunctive test for mildly abnormal cytologic smears in women > or = 50 years of age.

Lin CT, Tseng CJ, Lai CH, Hsueh S, Huang HJ, Law KS.

J Reprod Med. 2000 Apr;45(4):345-50.

PMID:
10804494
18.

Human papillomavirus DNA testing for cervical cancer screening in low-resource settings.

Kuhn L, Denny L, Pollack A, Lorincz A, Richart RM, Wright TC.

J Natl Cancer Inst. 2000 May 17;92(10):818-25.

PMID:
10814677
19.

Contribution of human papillomavirus testing by hybrid capture in the triage of women with repeated abnormal pap smears before colposcopy referral.

Fait G, Kupferminc MJ, Daniel Y, Geva E, Ron IG, Lessing JB, Bar-Am A.

Gynecol Oncol. 2000 Nov;79(2):177-80.

PMID:
11063640
20.

The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.

Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M.

J Natl Cancer Inst. 2005 Jul 20;97(14):1072-9.

PMID:
16030305

Supplemental Content

Support Center